Oral Presentation 12th Australian Peptide Conference 2017

Plants as biofactories for producing peptide-based pharmaceuticals (#28)

David J Craik 1 , Edward Gilding 2 , Mark Jackson 2 , Georgianna Kae Oguis 2 , Haiou Qu 2 , Bronwyn Smithies 2 , Kuok Yap 2
  1. ARC Centre of Excellence for Innovations in Peptide and Protein Science, University of Queensland, Brisbane, QLD, Australia
  2. Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia

Naturally occurring cyclic peptides offer great potential as leads for drug design. This talk will focus on a class of cyclic peptides known as cyclotides, which are topologically unique in that they have a head-to-tail cyclised peptide backbone and a cystine knotted arrangement of disulfide bonds. This makes them exceptionally stable to chemical, thermal or enzymatic treatments and, indeed, they are amongst nature’s most stable proteins. Because of their exceptional stability and well-defined structures cyclotides make excellent templates for drug design applications. This presentation will describe the discovery of cyclotides in plants, their structural characterization, and applications in drug design for the treatment of cancer, obesity, autoimmune disease (multiple sclerosis) and pain, as well as our efforts towards the expression of pharmaceutical cyclotides and other cyclic peptides in plant ‘biofactories’, particularly in Arabidopsis, tobacco and petunia.

  1. Craik D J, Du J: Cyclotides as drug design scaffolds. Current Opinion in Chemical Biology (2017) 38, 8-16.
  2. Craik D J, Weidmann J, de Veer S J: Cyclotides as tools in chemical biology. Accounts of Chemical Research (2017) 50, 1557-1565.